Netflix poaches CFO from Activision Blizzard - source

mutlugazete.com
ImmunoGen, Inc. (IMGN) was a big mover last session, as the company saw its shares rise more than 5% on the day. The stock moved up after the company raised $200 million through a non-dilutive royalty transaction with TPG Special Situations Partners for its breast cancer treatment Kadcyla. This led to solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above the volatile price range of $7.44–$8.69 over the past one-month time frame. This med-drugs industry stock witnessed one negative estimate revision in the past 30 days. The Zacks Consensus Estimate however remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future. ImmunoGen has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%. However, a better-ranked stock in the same space is Flamel Technologies SA (FLML), sporting a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IMMUNOGEN INC (IMGN): Free Stock Analysis Report FLAMEL TECH (FLML): Free Stock Analysis Report To read this article on Zacks.com click here. View comments
Empower Your Future: 30 Exciting Business Ideas Beyond 9-5
Discover 30 innovative business ideas to help you break free from the 9-5 routine and take control of your future.